Skip to main content

Advertisement

SpringerLink
Log in

Cisplatinum and BCNU chemotherapy in primary glioblastoma patients

  • Clinical Study-Patient Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Background The prognosis of patients with glioblastoma is very poor with a mean survival of 10–12 months. Currently available treatment options are multimodal, which include surgery, radiotherapy, and chemotherapy. However, these have been shown to improve survival only marginally in glioblastoma multiforme (GBM) patients. Methylated methylguanine methyltransferase (MGMT) promoter is correlated with improved progression-free and overall survival in patients treated with alkylating agents. Strategies to overcome MGMT-mediated chemoresistance are being actively investigated. Methods A retrospective analysis on 160 adult patients (≥16 years) treated for histologically confirmed GBM between 2003 and 2005 at our Institution was performed. All patients were treated with conventional fractionated radiotherapy and a combined chemotherapy treatment with Cisplatin (CDDP) (100 mg/sqm on day 1) and carmustine (BCNU) (160 mg/sqm on day 2); the treatment was repeated every 6 weeks for five cycles. Toxicity, progression free survival and overall survival were assessed. Results The median number of chemotherapy cycles delivered to each patient was 5 (range 3–6), with no patients discontinuing treatment because of refusal or toxicity. Dose reduction was required in 16 patients (10%), and all patients completed radiotherapy, whereas 5 patients discontinued chemotherapy before completing all planned cycles for disease progression. The primary toxicities were: neutropenia (grade 3–4: 23%), thrombocytopenia (grade 3–4: 18.5%), and nausea and vomiting (13%). Median progression-free survival times and 1-year progression free survival were 7.6 months (95% CI 6.6–8.5) and 17.3%, respectively. OS was 15.6 months (95% CI 14.1–17.1). Conclusions Our results for PFS and overall survival are comparable with those obtained with temozolomide, but the toxicity occurring in our series was more frequent and persistent. The toxicity, and mainly the modalities of administration associated with cisplatin and BCNU combination, argues against future use in the treatment of patients with GBM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in GBM. N Engl J Med 352(10):997–1003. doi:10.1056/NEJMoa043331

    Article  PubMed  CAS  Google Scholar 

  2. Kaina B, Christmann M, Naumann S, Roos WP (2007) MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 6(8):1079–1099. doi:10.1016/j.dnarep.2007.03.008

    Article  CAS  Google Scholar 

  3. Tanaka S, Kobayashi I, Utsuki S, Oka H, Yasui Y, Fujii K (2005) Down-regulation of O6-methylguanine-DNA methyltransferase gene expression in gliomas by platinum compounds. Oncol Rep 14(5):1275–1280

    PubMed  CAS  Google Scholar 

  4. D’Atri S, Graziani G, Lacal PM, Nisticò V, Gilberti S, Faraoni I, Watson AJ, Bonmassar E, Margison GP (2000) Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. J Pharmacol Exp Ther 294(2):664–671

    PubMed  Google Scholar 

  5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330

    Google Scholar 

  6. Walker MD, Alexander E Jr, Hunt WE et al (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333–343

    Article  PubMed  CAS  Google Scholar 

  7. Walker MD, Green SB, Byar DP et al (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323–1329

    PubMed  CAS  Google Scholar 

  8. Brandes AA, Tosoni A, Amista P et al (2004) How effective is BCNU in recurrent GBM in the modern era? A phase II trial. Neurology 63:1281–1284

    PubMed  CAS  Google Scholar 

  9. Chang SM, Prados MD, Yung WK et al (2004) Phase II study of neoadjuvant 1,3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium trial. Cancer 100:1712–1716. doi:10.1002/cncr.20157

    Article  PubMed  CAS  Google Scholar 

  10. Raizer JJ, Malkin MG, Kleber M et al (2004) Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. Neuro-oncol 6:247–252. doi:10.1215/S1152851704000122

    Article  PubMed  CAS  Google Scholar 

  11. Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, Huang W, Parker R (2006) In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res 12(15):4523–4532. doi:10.1158/1078-0432.CCR-05-1830

    Article  PubMed  CAS  Google Scholar 

  12. Boiardi A, Eoli M, Salmaggi A, Pollo B, Milanesi I, Broggi G, Silvani A (2000) Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas. J Neurooncol 49(1):71–75. doi:10.1023/A:1006489919811

    Article  PubMed  CAS  Google Scholar 

  13. Silvani A, Eoli M, Salmaggi A, Lamperti E, Maccagnano E, Broggi G, Boiardi A (2004) Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. J Neurooncol 66(1–2):203–208. doi:10.1023/B:NEON.0000013479.64348.69

    Article  PubMed  Google Scholar 

  14. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343(19):1350–1354. doi:10.1056/NEJM200011093431901

    Article  PubMed  CAS  Google Scholar 

  15. Buckner JC, Ballman KV, Michalak JC, Burton GV, Cascino TL, Schomberg PJ, Hawkins RB, Scheithauer BW, Sandler HM, Marks RS, O’Fallon JR (2006) North Central Cancer Treatment Group 93-72-52; Southwest Oncology Group 9503 Trials. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. J Clin Oncol 24(24):3871–3879. doi:10.1200/JCO.2005.04.6979

    Article  PubMed  CAS  Google Scholar 

  16. Frenay M, Giroux B, Khoury S, Derlon JM, Namer M (1991) Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur J Cancer 27(7):852–856

    Article  PubMed  CAS  Google Scholar 

  17. Fetell MR, Grossman SA, Fisher JD et al (1997) Preirradiation paclitaxel in GBM multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol 15:3121–3128

    PubMed  CAS  Google Scholar 

  18. Ciusani E, Balzarotti M, Calatozzolo C, de Grazia U, Boiardi A, Salmaggi A, Croci D (2007) Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines. Oncol Res 16(10):453–463. doi:10.3727/096504007783338340

    Article  PubMed  CAS  Google Scholar 

  19. Sher DJ, Henson JW, Avutu B, Hochberg FH, Batchelor TT, Martuza RL, Barker FG II, Loeffler JS, Chakravarti A (2008) The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed GBM. J Neurooncol 88(1):43–50

    Google Scholar 

  20. Osoba D, Brada M, Yung WK, Prados M (2000) Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent GBM multiforme. J Clin Oncol 18(7):1481–1491

    PubMed  CAS  Google Scholar 

  21. Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, Mason W, Mirimanoff RO, Baumert BG, Eisenhauer E, Forsyth P, Bottomley A, EORTC Radiotherapy Group; National Cancer Institute of Canada Clinical Trials Group (2005) Health-related quality of life in patients with GBM: a randomised controlled trial. Lancet Oncol 6(12):937–944. doi:10.1016/S1470-2045(05)70432-0

    Google Scholar 

  22. Sghirlanzoni A, Silvani A, Scaioli V, Pareyson D, Marchesan R, Boiardi A (1992) Cisplatin neuropathy in brain tumor chemotherapy. Ital J Neurol Sci 13(4):311–315. doi:10.1007/BF02223095

    Article  PubMed  CAS  Google Scholar 

  23. Meyers CA, Brown PD (2006) Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 24:1305–1309. doi:10.1200/JCO.2005.04.6086

    Article  PubMed  Google Scholar 

  24. Lamers LM, Stupp R, van den Bent MJ, Al MJ, Gorlia T, Wasserfallen JB, Mittmann N, Jin Seung S, Crott R, Uyl-de Groot CA (2008) Cost-effectiveness of temozolomide for the treatment of newly diagnosed GBM multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cancer 112(6):1337–1344. doi:10.1002/cncr.23297

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto Nazionale Neurologico Carlo Besta, Milan, Italy

    Antonio Silvani, Paola Gaviani, Elena A. Lamperti, Marica Eoli, Chiara Falcone, Francesco DiMeco, Ida M. Milanesi, Alessandra Erbetta, Amerigo Boiardi, Laura Fariselli & Andrea Salmaggi

Authors
  1. Antonio Silvani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paola Gaviani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elena A. Lamperti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marica Eoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chiara Falcone
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Francesco DiMeco
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ida M. Milanesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alessandra Erbetta
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Amerigo Boiardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Laura Fariselli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Andrea Salmaggi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio Silvani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Silvani, A., Gaviani, P., Lamperti, E.A. et al. Cisplatinum and BCNU chemotherapy in primary glioblastoma patients. J Neurooncol 94, 57–62 (2009). https://doi.org/10.1007/s11060-009-9800-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-009-9800-0

Keywords

Search

Navigation